疳积散合增食膏治疗小儿厌食病(脾虚食积型)的疗效观察OA
Observation on the Curative Effect of on Ganji Powder Combined with Zengshi Oral Paste in the Treatment of Anorexia Disease of Children with Spleen Deficiency and Dyspepsia
目的:探讨疳积散合增食膏对小儿厌食病(脾虚食积型)患儿的临床疗效及安全性.方法:选取2022 年7 月—2023 年12 月在铜陵市中医医院门诊就诊的厌食病患儿为研究对象,采用随机数字表法分为4 组,布拉氏酵母菌组(36 例)采用单一布拉氏酵母菌口服;疳积散组(41 例)单用疳积散外敷穴位治疗;增食膏组(49 例)单用增食膏口服;联合组(76 例)采用疳积散外敷神阙、命门两穴位,联合增食膏口服(铜陵市中医医院院内制剂).4 组均治疗1 个疗程.观察 4 组患儿临床疗效、患儿食量恢复正常时间及体质量增加量、中医证候积分、营养指标水平、不良反应及随访半年情况等指标.结果:联合组总有效率为89.47%(68/76),布拉氏酵母菌组 58.33%(21/36),疳积散组 70.73%(29/41),增食膏组75.51%(37/49),联合组的总有效率、患儿食量恢复正常时间及体质量增加量,主症及次症、舌脉等中医证候积分,蛋白质、体脂肪、肌肉量、基础代谢率、转铁蛋白、视黄醇结合蛋白、前白蛋白、血红蛋白、平均血红蛋白含量、二羟基维生素 D 等营养指标均明显优于布拉氏酵母菌组、疳积散组与增食膏组(P<0.05,P<0.01);疳积散组与增食膏组的各项指标均优于布拉氏酵母菌组(P<0.05,P<0.01);各组治疗期间未出现严重的不良反应情况,且随访半年后联合组的复发率最低,但差异无统计学意义(P>0.05).结论:基于疳积散合增食膏治疗小儿厌食病(脾虚食积型),能显著降低患儿临床症状,患儿胃肠功能恢复良好,临床效果十分显著且安全性较高.
Objective:To explore the clinical efficacy and safety research on children with anorexia-spleen deficiency and dyspepsia based on Ganji Powder combined with Zengshi Oral Paste.Methods:Children with anorexia attending the outpatient clinic of Tongling Traditional Chinese Medicine Hospital from July 2022 to December 2023 were selected for the study,and were divided into four groups using the random number table method;the Saccharomyces boulardii group(36 cases)was treated with a single Saccharomyces boulardii orally,the Ganji Powder group(41 cases)was treated with Ganji Powder externally applied to the acupoints alone,the Zengshi Oral Paste group(49 cases)was treated with Zengshi Oral Paste orally alone,and the combined group used the The combined group was treated with Ganji Powder applied externally to two acupoints,Shenque and Mingmen,and combined with Zengshi Oral Paste(an in-hospital preparation).All four groups were treated for one treating course.The clinical efficacy of the children in the four groups,the time for the children's food intake to return to normal and the amount of increase in body mass,the points of Chinese medicine symptoms,the level of nutritional indexes,the adverse reactions and the six-month follow-up were observed.Results:The total effective rate was 89.47%(68/76)in the combined group,58.33%(21/36)in the Saccharomyces boulardii group,70.73%(29/41)in the Ganji Powder group,and 75.51%(37/49)in the Zengshi Oral Paste group.The total effective rate of the combined group and the time for the return of the normal food intake and the increase of the body mass of the children,the Chinese medicine symptom scores of the main evidence and the secondary evidence,the tongue and pulse,and the levels of the proteins,the body fats,the muscle mass,the basal metabolic rate,the transferrin,the retinol-binding protein,the pre-albumin Nutritional indicators such as protein,body fat,muscle mass,basal metabolic rate,transferrin,retinol-binding protein,prealbumin,haemoglobin,average haemoglobin content and dihydroxyvitamin D were all better than those of the Saccharomyces boulardii group,the noma group and the Zengshi Oral Paste group(P<0.05,P<0.01);All indicators of the Ganji Powder and Zengshi Oral Paste were superior to those of Saccharomyces boulardii group.(P<0.05).There were no serious adverse reaction situations during the treatment period of each group,and the relapse rate of the combined group was the lowest after six months of follow-up.Conclusion:The treatment of children's anorexia with spleen deficiency and dyspepsia based on Ganji Powder and Zengshi Oral Paste can significantly reduce children's clinical symptoms,and the children's gastrointestinal function recovered well,with a significant clinical effect and high safety.
石锦梅;赵丽莹;胡少华;汪江涛;秦宗富;魏昆;曹征芳;曹美平
安徽中医药大学铜陵附属医院暨铜陵市中医医院,安徽 铜陵 244000安徽中医药大学铜陵附属医院暨铜陵市中医医院,安徽 铜陵 244000安徽中医药大学铜陵附属医院暨铜陵市中医医院,安徽 铜陵 244000安徽中医药大学铜陵附属医院暨铜陵市中医医院,安徽 铜陵 244000安徽中医药大学铜陵附属医院暨铜陵市中医医院,安徽 铜陵 244000安徽中医药大学铜陵附属医院暨铜陵市中医医院,安徽 铜陵 244000安徽中医药大学铜陵附属医院暨铜陵市中医医院,安徽 铜陵 244000安徽中医药大学铜陵附属医院暨铜陵市中医医院,安徽 铜陵 244000
医药卫生
疳积散增食膏小儿厌食脾虚食积
Ganji PowderZengshi Oral PastePaediatric anorexiaSpleen deficiency and dyspepsia
《中医药学报》 2026 (7)
61-66,6
安徽省中医药传承创新科研项目(2022CCYB25)
评论